PerkinElmer, Inc. unveiled a new series of AlphaLISA “No Wash” immunoassay kits for advanced biomarker research in multiple key disease states, including angiogenesis, inflammation, and cancer.
This release brings the number of available AlphaLISA assays to 54 kits, and is a broad expansion of PerkinElmer’s breakthrough ELISA-alternative ALPHA (Amplified Luminescent Proximity Homogeneous Assay) technology portfolio.
AlphaLISA is a proprietary bead-based platform that allows the highly-sensitive detection of biomolecules and biomolecular interactions without wash steps, enabling researchers to measure very low affinity interactions. AlphaLISA saves time, eliminates labor intensive processes that are difficult to automate, and overcomes other traditional limitations of ELISAs, such as assay variation and narrow dynamic range. The technology’s sensitivity and homogeneity also enables savings in sample and antibodies usage, according to PerkinElmer.
In addition to angiogenesis, inflammation, and cancer biomarker research assays, the AlphaLISA kits feature panels of assays for research in Alzheimer’s, cardiovascular, and metabolic disorders.
AlphaLISA is a proprietary homogeneous bead-based assay, and has been validated with PerkinElmer’s EnVision Multiplate Label Readers, a highly flexible modular system that detects several assay formats, including TR-FRET, luminescence, and fluorescence.
Published in Drug Discovery & Development magazine: Vol. 12, No. 5, May, 2009, p.35.